CRISPR Therapeutics AG (NASDAQ:CRSP) Position Reduced by Entropy Technologies LP

Entropy Technologies LP reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 48.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,905 shares of the company’s stock after selling 7,497 shares during the quarter. Entropy Technologies LP’s holdings in CRISPR Therapeutics were worth $371,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Capital International Investors grew its holdings in CRISPR Therapeutics by 27.8% during the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after acquiring an additional 1,702,624 shares during the period. SR One Capital Management LP acquired a new position in shares of CRISPR Therapeutics in the 1st quarter valued at $71,496,000. Farallon Capital Management LLC acquired a new stake in CRISPR Therapeutics during the 2nd quarter worth about $28,625,000. Avoro Capital Advisors LLC purchased a new stake in CRISPR Therapeutics during the first quarter valued at about $28,599,000. Finally, Marshall Wace LLP acquired a new position in shares of CRISPR Therapeutics in the second quarter worth about $10,078,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the sale, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,382 shares of company stock worth $1,917,679. Company insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CRSP. Barclays reduced their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Rodman & Renshaw started coverage on CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective for the company. Finally, Chardan Capital dropped their price objective on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $74.94.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $47.25 on Friday. CRISPR Therapeutics AG has a 52 week low of $43.42 and a 52 week high of $91.10. The firm has a market capitalization of $4.03 billion, a PE ratio of -16.70 and a beta of 1.67. The business’s 50-day simple moving average is $47.88 and its 200-day simple moving average is $52.04.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the prior year, the company earned ($1.41) EPS. Research analysts forecast that CRISPR Therapeutics AG will post -5.2 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.